By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Caladrius Biosciences (Formerly Known As NeoStem, Inc.)  

420 Lexington Ave, Suite 350

New York  New York  10170  U.S.A.
Phone: 212-584-4180 Fax: 425-696-4651


SEARCH JOBS


Industry
Services

Segment
Biotechnology





Company News
Caladrius Biosciences (CLBS) Closes The Sale Of Its Remaining Interest In PCT To Hitachi Chemical Co., Ltd. For $75 Million 5/19/2017 7:56:10 AM
Caladrius Biosciences (CLBS) Announces 2017 First Quarter Financial Results 5/16/2017 10:51:46 AM
Caladrius Biosciences (CLBS) To Hold 2017 Annual Stockholder Meeting On May 16 4/11/2017 10:59:01 AM
Caladrius Biosciences (CLBS) Announces Addition Of Four Clinical Sites, Including Joslin Diabetes Center, For The Ongoing Phase II Study Of CLBS03 In T1D 4/3/2017 1:47:03 PM
Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences (CLBS) The Remaining 80.1% Interest In PCT For $75 Million 3/17/2017 11:08:03 AM
Caladrius Biosciences (CLBS) Announces 2016 Fourth Quarter And Full Year Financial Results 3/17/2017 10:59:55 AM
Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences (CLBS) The Remaining 80.1% Interest In PCT For $75 Million 3/17/2017 7:54:59 AM
Caladrius Biosciences (CLBS) To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time 3/13/2017 8:37:29 AM
Caladrius Biosciences (CLBS) Awarded $12.2 Million Grant From CIRM In Support Of Phase II Clinical Trial Of CLBS03 To Treat Type 1 Diabetes 2/24/2017 8:29:00 AM
Caladrius Biosciences (CLBS) Release: Biotech Announces Addition Of Three Clinical Sites, Including UCSF, For The Ongoing Phase 2 Study Of CLBS03 In T1D 1/25/2017 7:41:35 AM
12345678910...
//-->